樺花粉アレルギー(Birch Pollen Allergy)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Birch Pollen Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Birch Pollen Allergy – Overview 7
Pipeline Products for Birch Pollen Allergy – Comparative Analysis 8
Birch Pollen Allergy – Therapeutics under Development by Companies 9
Birch Pollen Allergy – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Birch Pollen Allergy – Products under Development by Companies 13
Birch Pollen Allergy – Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
Allergopharma Joachim Ganzer KG 15
Anergis SA 16
Biomay AG 17
Circassia Pharmaceuticals plc 18
HAL Allergy BV 19
Stallergenes S.A. 20
Birch Pollen Allergy – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ALK Birch Pollen Vaccine – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AllerT – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Birch-SPIRE – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BM-31 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Drug for Birch Pollen Allergy – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PL-102 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rBet v1 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
rBet v1-FV – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Birch Pollen Allergy – Recent Pipeline Updates 38
Birch Pollen Allergy – Dormant Projects 40
Birch Pollen Allergy – Discontinued Products 41
Birch Pollen Allergy – Product Development Milestones 42
Featured News & Press Releases 42
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 42
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 42
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 43
Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 43
Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis’s Birch Pollen Allergy Vaccine AllerT 43
Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 44
Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT 45
Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis’s COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment 45
Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen 46
Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49